Clinical Trial Update: Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old) [Phase 4]

View source ↗

Summary

A Phase 4 trial at UTMB compares immune responses to two versus three doses of an HPV vaccine in adults aged 27-45, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• HPV vaccine

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Immunization, HPV Infection | Phase 4 | Status: RECRUITING